Cytokinetics CYTK Accounts Receivable
Accounts Receivable at other companies
Other financials
Where this comes from
Reported directly by Cytokinetics in its filing.
Tagged under the XBRL concept us-gaap:AccountsReceivableNetCurrent.
The official record: Cytokinetics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Cytokinetics's accounts receivable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Cytokinetics's accounts receivable?
- Cytokinetics (CYTK) reported accounts receivable of $6.83M in Q1 2026.
- How has Cytokinetics's accounts receivable changed year-over-year?
- Cytokinetics's accounts receivable increased by 239.3% year-over-year, from $2.01M to $6.83M.
- What is the long-term trend for Cytokinetics's accounts receivable?
- Over 5 years (2020 to 2025), Cytokinetics's accounts receivable has grown at a 32.1% compound annual growth rate (CAGR), from $4.42M to $17.76M.
- What does accounts receivable mean?
- The amount of money customers owe the company for products or services already provided.
- How do you interpret accounts receivable?
- An increase may indicate rising sales or slower collections, while a decrease suggests faster cash conversion or lower sales volume.
- How does accounts receivable compare across companies?
- Commercial-stage pharmaceutical companies typically have higher receivables compared to early-stage clinical development firms.